Immunoadjuvant Activity of Fucoidans from the Brown Alga <i>Fucus evanescens</i>

• Main Authors: Tatyana A. Kuznetsova, Tatyana P. Smolina, Ilona D. Makarenkova, Lydmila A. Ivanushko, Elena V. Persiyanova, Svetlana P. Ermakova, Artem S. Silchenko, Tatyana S. Zaporozhets, Natalya N. Besednova, Lydmila N. Fedyanina, Sergey P. Kryzhanovsky
• Format: Article
• Language: English
• Published: MDPI AG 2020-03-01
• Series: Marine Drugs
• Subjects: adjuvants; vaccines; fucoidans; innate and adaptive immunity
• Online Access: https://www.mdpi.com/1660-3397/18/3/155

The study presents the results of a comparative evaluation of the effect of structural modifications of fucoidans from the brown alga Fucus evanescens (native, highly purified product of fucoidan enzymatic hydrolysis, a new regular 1&#8594;3;1&#8594;4-&#945;-L-fucan, sulphated mainly at C2 and acetylated at C4 of the fucose residue) on the effector functions of innate and adaptive immunity cells in vitro and in vivo. Using flow cytometry, we found that all examined fucoidans induce the maturation of dendritic cells, enhance the ability of neutrophils to migrate and adhere, activate monocytes and enhance their antigen-presenting functions, and increase the cytotoxic potential of natural killers. Fucoidans increase the production of hepatitis B virus (HBs) specific IgG and cytokine Th1 (IFN-&#947;, TNF-&#945;) and Th2 (IL-4) profiles in vivo. The data obtained suggest that in vitro and in vivo adjuvant effects of the products of fucoidan enzymatic hydrolysis with regular structural characteristics are comparable to those of the native fucoidan. Based on these data, the products of fucoidan enzymatic hydrolysis can be considered as an effective and safe candidate adjuvant to improve the efficacy of prophylactic and therapeutic vaccines.